• Publications
  • Influence
Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging α(v)β(3) integrin levels.
The administration of (18)F-FPPRGD2 was well tolerated, with no marked effects on vital signs, ECG readings, or laboratory values, and tracer biodistribution and dosimetric properties, time-activity curves, and the stability of laboratory values were evaluated.
Circulating Tumor Microemboli Diagnostics for Patients with Non–Small-Cell Lung Cancer
CTM may add utility for lung cancer diagnosis during imaging evaluation using a sensitive detection platform to identify stage I non–small-cell lung cancer patients undergoing imaging evaluation.
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
This study validates the previous findings that MTV independently predicts outcomes in head-and-neck cancer and should be considered as a potential risk-stratifying biomarker in future studies of HNC.
Thyroid carcinoma, version 2.2014.
A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.
Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia.
A 71-year-old man with coronary artery disease, coronary artery bypass grafting in 2000, baseline ejection fraction of 0.24, and implantation of a single chamber implanted cardioverter defibrillator
Novel Strategy for a Cocktail 18F-Fluoride and 18F-FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot-Phase Study
A pilot-phase prospective trial demonstrates that the combined 18F/18F-FDG administration followed by a single PET/CT scan is feasible for cancer detection and opens the possibility for improved patient care and reduction in health care costs.
Radioembolization Dosimetry: The Road Ahead
The aim of this review is to give insight into the latest and most important developments in RE dosimetry and to suggest future directions on patient selection, individualized treatment planning, and study designs.
Pilot Comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer
68Ga-PSMA-11 and 68Ga-RM2 had distinct biodistributions in this small cohort of patients with biochemically recurrent prostate cancer and additional work is needed to understand the expression of PSMA and gastrin-releasing peptide receptors in different types of prostate cancer.
Anaplastic Thyroid Carcinoma, Version 2.2015.
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic
Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
It is found that 68Ga-PSMA-11 PET can be used to identify prostate cancer, while MR imaging provides detailed anatomic guidance and may inform the need for and extent of pelvic node dissection.